Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Melanoma Clinical Trials

A listing of Melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (581) clinical trials

Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye

The purpose of this study is to see if the combination of entinostat and pembrolizumab can be an effective treatment for patients with melanoma of the eye (uveal melanoma) that has spread to other sites of the body (metastatic disease). Pembrolizumab is an antibody that helps the immune system to ...

Phase

Yervoy Pregnancy Surveillance Study

The study is a global safety surveillance study of pregnancy outcomes in women who were exposed to ipilimumab during pregnancy and pediatric outcomes up to 5 years of age

Phase N/A

Evaluate Efficacy Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma Patients

Primary Objective: The primary objective of this study is to evaluate the overall tumor sites response (objective response rate [ORR]) to OBP-301 in both injected and noninjected lesions up to and including Week 24 in patients with unresectable/unresected Stage III and IV melanoma. The ORR is defined as the rate ...

Phase

Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients

To improve the efficacy of immunotherapy for cancer, recent studies focused on specific targets to redirect the immune network toward eradicating a variety of tumors and ameliorating the self-destructive process. A clinically relevant immune escape mechanism in melanoma is the activation of the Programmed cell Death-1 (PD-1) receptor on infiltrating ...

Phase

Dendritic Cell Activating Scaffold in Melanoma

After agreeing to participate you will be asked to undergo some screening tests or procedures to confirm that you are eligible for the study. Many of these test and procedures are likely to be part of regular cancer care and may be done even if it turns out that you ...

Phase

Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era

All the patients enrolled are confirmed without any evidence of distant metastasis. All the patients receive extended resection to primary tumor and post-surgery RT. The patients are prescribed a 65-70Gy to CTV1 (high-risk regions including tumor bed), 50-55Gy to CTV2(low-risk regions) using Intensity-modulated radiotherapy (IMRT). The Prophylactic irradiation to upper ...

Phase

Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists

The purpose of this study is to learn what effects (good and bad) an experimental vaccine (LPV7) plus tetanus peptide and other substances called polyICLC, resiquimod, and Montanide ISA-51 have on you and your melanoma. We will also look at whether the experimental vaccine and these drugs cause any changes ...

Phase

Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging

A topical agent is applied to suspicious skin lesions and imaged. The images are analyzed to provide a score that correlates with the probability for the presence of melanoma in the lesion.

Phase N/A

A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma

In this study, we plan to enroll 30 patients with advanced melanoma patients who have failed at least one systemic treatment regimen. The therapeutic regimen is temozolomide, 300mg,po, d1-5, apatinib, 500 mg, qd, po, d1-28, Every 28 days for 1 cycles, the primary end point was PFS, the secondary end ...

Phase

Ibrutinib in Treating Patients With Refractory Stage IV Cutaneous Melanoma

PRIMARY OBJECTIVES: I. Estimate rate of objective response (OR: complete response [CR] + partial response [PR]) to ibrutinib administered as single agent in patients with immune checkpoint inhibitor-refractory and mitogen-activated protein kinase (MAPK) inhibitor-refractory (if B-Raf proto-oncogene, serine/threonine kinase [BRAF]V600-mutant) distant metastatic cutaneous melanoma. SECONDARY OBJECTIVES: I. Estimate progression-free survival ...

Phase